

Um Novo Processo para a Obtenção do Antimoniato de Meglumina, Visando a Produção do Medicamento Genérico

Carvalho, A. S.; Duarte, S. L.; Costa, J. C. S.; Boechat, N.*

Rev. Virtual Quim., 2015, XX (XX), S1-S8. Data de publicação na Web: 7 de fevereiro de 2015

<http://www.uff.br/rvq>




Figura 1. Espectros de ^1H RMN e COSY (400 e 50 MHz) do Glucantime[®] -Lote 104557




Figura 2. Espectros de ¹H NMR e COSY (400 e 50 MHz) do Glucantime[®] -Lote 252 V0701




Figura 4. Espectros de ¹H NMR e COSY (400 e 50 MHz) do antimoniato de meglumina TAM 02/03




Figura 5. Espectro de massa do Glucantime[®] -Lote 104557




Figura 6. Espectro de massas do Glucantime[®] -Lote 252 V0701




Figura 7. Espectro de massas do antimoniato de meglumina TAM 01/03




Figura 8. Espectro de massas do antimoniato de meglumina TAM 02/03




Figura 9. Espectro de infravermelho do antimoniato de meglumina TAM 01/03 (KBr)